During the recent session, Prometheus Biosciences Inc. (NASDAQ:RXDX)’s traded shares were 1.17 million. At the last check today, the stock’s price was $198.60, reflecting an intraday loss of -0.04% or -$0.07. The 52-week high for the RXDX share is $198.99, that puts it down -0.2 from that peak though still a striking 88.77% gain since the share price plummeted to a 52-week low of $22.31. The company’s market capitalization is $9.53B, and the average intraday trading volume over the past 10 days was 1.23 million shares, and the average trade volume was 1.11 million shares over the past three months.

Prometheus Biosciences Inc. (RXDX) received a consensus recommendation of a Hold from analysts. That translates to a mean rating of 2.80. RXDX has a Sell rating from 0 analyst(s) out of 9 analysts who have looked at this stock. 8 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.93.

Prometheus Biosciences Inc. (NASDAQ:RXDX) trade information

Prometheus Biosciences Inc. (RXDX) registered a -0.04% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -0.04% in intraday trading to $198.60 this Wednesday, 05/24/23, hitting a weekly high. The stock’s 5-day price performance is 2.82%, and it has moved by 2.20% in 30 days. Based on these gigs, the overall price performance for the year is 606.51%. The short interest in Prometheus Biosciences Inc. (NASDAQ:RXDX) is 4.9 million shares and it means that shorts have 3.04 day(s) to cover.

The consensus price target of analysts on Wall Street is $195.00, which implies a decrease of -1.85% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $160.00 and $200.00 respectively. As a result, RXDX is trading at a discount of -0.7% off the target high and 19.44% off the low.

Prometheus Biosciences Inc. (RXDX) estimates and forecasts

Statistics show that Prometheus Biosciences Inc. has underperformed its competitors in share price, compared to the industry in which it operates. Prometheus Biosciences Inc. (RXDX) shares have gone up 330.62% during the last six months, with a year-to-date growth rate less than the industry average at -10.03% against 11.40. Yet analysts are ramping up their growth forecast for the fiscal year 2023. Revenue is predicted to shrink -8.10% this quarter and then drop -8.90% in the quarter after that. In the rating firms’ projections, revenue will decrease -61.50% compared to the previous financial year.

Revenue for the current quarter is expected to be $600k as predicted by 4 analyst(s). Meanwhile, a consensus of 4 analyst(s) estimates revenue growth to $640k by the end of Sep 2023. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $1.27 million and $968k respectively. In this case, analysts expect current quarter sales to shrink by -52.70% and then drop by -33.90% in the coming quarter.

While earnings are projected to return -21.20% in 2023.

RXDX Dividends

Prometheus Biosciences Inc. is due to release its next quarterly earnings on May 13. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Prometheus Biosciences Inc. (NASDAQ:RXDX)’s Major holders

Prometheus Biosciences Inc. insiders own 16.61% of total outstanding shares while institutional holders control 81.01%, with the float percentage being 97.15%. RTW Investments LP is the largest shareholder of the company, while 311 institutions own stock in it. As of Mar 30, 2023, the company held over 3.27 million shares (or 6.84% of all shares), a total value of $351.16 million in shares.

The next largest institutional holding, with 2.8 million shares, is of Blackrock Inc.’s that is approximately 5.86% of outstanding shares. At the market price on Mar 30, 2023, these shares were valued at $300.48 million.

Also, the Mutual Funds coming in first place with the largest holdings of Prometheus Biosciences Inc. (RXDX) shares are Vanguard Total Stock Market Index Fund and Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund. Data provided on Dec 30, 2022 indicates that Vanguard Total Stock Market Index Fund owns about 1.06 million shares. This amounts to just over 2.23 percent of the company’s overall shares, with a $116.67 million market value. The same data shows that the other fund manager holds slightly less at 0.83 million, or about 1.75% of the stock, which is worth about $91.62 million.